Mycophenolate-containing medications are widely used to prevent organ rejection in transplant recipients and to treat (off label) some autoimmune conditions such as lupus; however, use of these immunosuppressive agents during pregnancy is linked to a significantly increased risk of miscarriage …
GLP-1 receptor agonists (GLP-1 RAs) have redefined the standard of care for type 2 diabetes (T2D), especially in patients with cardiovascular disease (CVD), chronic kidney disease (CKD), obesity, or metabolic dysfunction-associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis (MASLD/MASH). These innovative therapies …
Underserved patient populations often face significant health disparities rooted in unaddressed social drivers of health (SDOH), such as food insecurity, housing instability, and limited access to care. These social needs directly contribute to poor health outcomes and preventable health complications. …
There is a critical and ongoing need to educate nurses and nurse practitioners, who often form the backbone of patient care delivery, about the presence and impact of unconscious bias in clinical settings. As essential connectors within the healthcare provider …
Despite guideline familiarity and awareness of lipid-lowering targets, many clinicians fail to translate this knowledge into clinical action, leaving patients at elevated risk for cardiovascular events. A key driver of this disconnect is therapeutic inertia—particularly regarding risk assessment, intensification of …
GLP-1 receptor agonists (GLP-1 RAs) have become a cornerstone of type 2 diabetes (T2D) treatment, with strong endorsements from the American Diabetes Association and the American Association of Clinical Endocrinology. Despite these clear guidelines, GLP-1 RAs remain significantly underutilized, as …
